Royal Bank of Canada Cuts Humana (NYSE:HUM) Price Target to $353.00

Humana (NYSE:HUM) had its target price decreased by equities researchers at Royal Bank of Canada from $415.00 to $353.00 in a note issued to investors on Thursday, Benzinga reports. The firm currently has an “outperform” rating on the insurance provider’s stock. Royal Bank of Canada’s price target indicates a potential upside of 15.39% from the company’s previous close.

HUM has been the topic of several other reports. Stephens decreased their price target on shares of Humana from $550.00 to $430.00 and set an “overweight” rating on the stock in a report on Friday, January 26th. UBS Group cut their target price on shares of Humana from $334.00 to $326.00 and set a “neutral” rating on the stock in a research report on Thursday. TD Cowen cut their target price on shares of Humana from $427.00 to $396.00 and set a “buy” rating on the stock in a research report on Tuesday, April 2nd. Barclays cut their target price on shares of Humana from $356.00 to $310.00 and set an “equal weight” rating on the stock in a research report on Tuesday, April 2nd. Finally, Truist Financial reiterated a “hold” rating and set a $550.00 target price on shares of Humana in a research report on Friday, January 19th. Eleven research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, Humana presently has a consensus rating of “Hold” and a consensus target price of $433.74.

Humana Trading Down 1.8 %

Shares of Humana stock opened at $305.91 on Thursday. The firm has a market capitalization of $36.86 billion, a PE ratio of 19.05, a price-to-earnings-growth ratio of 1.82 and a beta of 0.45. The company has a current ratio of 1.67, a quick ratio of 1.59 and a debt-to-equity ratio of 0.77. The firm’s 50 day moving average is $327.77 and its 200 day moving average is $394.49. Humana has a 1 year low of $299.23 and a 1 year high of $541.21.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.12 by $1.11. The company had revenue of $29.61 billion for the quarter, compared to analyst estimates of $28.52 billion. Humana had a net margin of 1.82% and a return on equity of 17.76%. The firm’s revenue was up 10.7% on a year-over-year basis. During the same period in the previous year, the firm posted $9.38 EPS. Equities research analysts forecast that Humana will post 16.07 earnings per share for the current fiscal year.

Insider Activity at Humana

In related news, Director Jorge S. Mesquita bought 545 shares of the company’s stock in a transaction that occurred on Tuesday, February 20th. The shares were bought at an average price of $367.09 per share, for a total transaction of $200,064.05. Following the transaction, the director now directly owns 2,578 shares of the company’s stock, valued at $946,358.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.32% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of HUM. Morgan Stanley increased its stake in Humana by 6.2% during the 3rd quarter. Morgan Stanley now owns 2,040,896 shares of the insurance provider’s stock valued at $992,938,000 after purchasing an additional 119,760 shares in the last quarter. Ameriprise Financial Inc. increased its stake in Humana by 35.9% during the 3rd quarter. Ameriprise Financial Inc. now owns 1,523,835 shares of the insurance provider’s stock valued at $741,409,000 after purchasing an additional 402,559 shares in the last quarter. Norges Bank bought a new stake in Humana during the 4th quarter valued at $676,800,000. Northern Trust Corp increased its stake in Humana by 5.1% during the 3rd quarter. Northern Trust Corp now owns 1,327,489 shares of the insurance provider’s stock valued at $645,850,000 after purchasing an additional 64,245 shares in the last quarter. Finally, Sanders Capital LLC bought a new stake in Humana during the 4th quarter valued at $489,300,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.